Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake

Rhea-AI Filing Summary

Lantern Pharma Inc. reported that Thomas A. Satterfield, Jr. beneficially owns 570,000 shares of Common Stock, representing 5.1% of the class. The filing breaks the position into 95,000 shares with sole voting/dispositive power and 475,000 shares with shared voting/dispositive power, and cites 11,254,697 shares outstanding as of March 13, 2026.

The filing lists specific holder vehicles: 45,000 shares held by Tomsat Investment & Trading Co., Inc.; 250,000 by Caldwell Mill Opportunity Fund, LLC; 150,000 by A.G. Family L.P.; and 30,000 by Satterfield Vintage Investments, L.P. Ownership links and control relationships are described in the filing.

Insights

Corporate Governance Specialist

Holder disclosed a 5.1% beneficial stake with mixed sole/shared control.

The filing shows a 570,000-share beneficial position with 95,000 shares under sole voting/dispositive power and 475,000 under shared power. The report cites an as of outstanding share count of 11,254,697, which establishes the 5.1% threshold.

Key dependencies are the named entities that hold shares and the control links (e.g., Tomsat Investment & Trading Co., Inc. as a vehicle). Future disclosures may clarify changes if any of those entities trade or reallocate holdings.

Securities Compliance Analyst

Schedule 13G was used to report passive/beneficial ownership structure and related parties.

The statement itemizes holdings across multiple entities and explains relationships (control, general partner roles). It follows Schedule 13G structure by providing voting and dispositive power breakdowns and an outstanding-share anchor date.

Material compliance points: the filing identifies affiliated vehicles and attributes shares accordingly, which helps satisfy beneficial‑ownership disclosure requirements under federal rules.

Key Figures

Beneficially owned: 570,000 shares Percent of class: 5.1% Shares outstanding: 11,254,697 shares +6 more

9 metrics

Beneficially owned 570,000 shares Total beneficial ownership reported in the Schedule 13G

Percent of class 5.1% Percent of common stock based on outstanding shares as of March 13, 2026

Shares outstanding 11,254,697 shares Shares outstanding cited from Form 10-K as of March 13, 2026

Sole voting/dispositive power 95,000 shares Shares with sole voting and dispositive power held by the reporting person

Shared voting/dispositive power 475,000 shares Shares with shared voting and dispositive power held by the reporting person

Tomsat Investment & Trading Co., Inc. 45,000 shares Shares held by the corporate vehicle controlled by Mr. Satterfield

Caldwell Mill Opportunity Fund, LLC 250,000 shares Shares held by the fund managed by an entity in which Mr. Satterfield owns 50%

A.G. Family L.P. 150,000 shares Shares held by a partnership managed by a general partner controlled by Mr. Satterfield

Satterfield Vintage Investments, L.P. 30,000 shares Shares held by the partnership majority-owned by other Satterfield vehicles

Key Terms

Schedule 13G, beneficially owned, shared dispositive power, sole voting power

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Lantern Pharma Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned regulatory

"Item 4. Ownership (a) Amount beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"6 | Shared Dispositive Power 475,000.00"

sole voting power regulatory

"5 | Sole Voting Power 95,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

How many Lantern Pharma (LTRN) shares does Thomas A. Satterfield, Jr. beneficially own?

He beneficially owns 570,000 shares of common stock. The filing breaks this into 95,000 sole-power shares and 475,000 shared-power shares, representing 5.1% of the class.

What is the basis for the 5.1% ownership figure in the Schedule 13G?

The 5.1% figure is based on 11,254,697 shares outstanding as of March 13, 2026. The filing cites that outstanding-share count from the issuer's Form 10-K for calculation.

Which entities hold shares on behalf of Mr. Satterfield according to the filing?

The filing lists holdings by Tomsat Investment & Trading Co., Inc. (45,000), Caldwell Mill Opportunity Fund, LLC (250,000), A.G. Family L.P. (150,000), and Satterfield Vintage Investments, L.P. (30,000).

How is voting and dispositive power allocated for the reported shares?

The filing reports 95,000 shares where Mr. Satterfield has sole voting and dispositive power, and 475,000 shares where he has shared voting and dispositive power.

Does the Schedule 13G describe control relationships among the holding vehicles?

Yes. It states Mr. Satterfield controls Tomsat Investment & Trading Co., Inc. and identifies management/control relationships for the other entities, including general partner and ownership links.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 10:53 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lantern Pharma Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

51654W101

(CUSIP Number)

03/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 51654W101

1

Names of Reporting Persons

Thomas A. Satterfield, Jr.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 95,000.00
6	Shared Voting Power 475,000.00
7	Sole Dispositive Power 95,000.00
8	Shared Dispositive Power 475,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

570,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: *Based on 11,254,697 shares of common stock of the issuer (the "Common Stock") outstanding as of March 13, 2026, as reported by the issuer in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lantern Pharma Inc.
(b)	Address of issuer's principal executive offices: 1920 McKinney Avenue, 7th Floor, Dallas, TX 75201
Item 2.
(a)	Name of person filing: Thomas A. Satterfield, Jr.
(b)	Address or principal business office or, if none, residence: 15 Colley Cove Drive Gulf Breeze, Florida 32561
(c)	Citizenship: Incorporated by reference from Item 4 of the Cover Page.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 51654W101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Incorporated by reference from Item 9 of the Cover Page.
(b)	Percent of class: Incorporated by reference from Item 11 of the Cover Page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Incorporated by reference from Item 5 of the Cover Page.
	(ii) Shared power to vote or to direct the vote: Incorporated by reference from Item 6 of the Cover Page.
	(iii) Sole power to dispose or to direct the disposition of: Incorporated by reference from Item 7 of the Cover Page.
	(iv) Shared power to dispose or to direct the disposition of: Incorporated by reference from Item 8 of the Cover Page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 45,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 250,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; 150,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 30,000 shares of common stock are held by Satterfield Vintage Investments, L.P. Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.'s equity, and Tomsat Investment & Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Thomas A. Satterfield, Jr.

Signature:	/s/ Thomas A. Satterfield, Jr.
Name/Title:	Thomas A. Satterfield, Jr.
Date:	04/03/2026